Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Italian Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group Trials. GROCTA Trials.
Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Pacini P, Gallo L, Sismondi P, Giai M, Genta F, Mustacchi G, Agostara B, Bolognesi A, Villa E, Schieppati G, Ausili Cefaro GP, Bellantone R, Farris A, Sassi M, Patrone F. Boccardo F, et al. Recent Results Cancer Res. 1998;152:453-70. doi: 10.1007/978-3-642-45769-2_44. Recent Results Cancer Res. 1998. PMID: 9928580 Review.
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, Piffanelli A, Scanni A, Sismondi P, Santi L, et al. Boccardo F, et al. J Clin Oncol. 1990 Aug;8(8):1310-20. doi: 10.1200/JCO.1990.8.8.1310. J Clin Oncol. 1990. PMID: 2199618 Clinical Trial.
Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA).
Boccardo F, Rubagotti A, Amoroso D, Perrotta A, Sismondi P, Farris A, Mesiti M, Gallo L, Pacini P, Villa E, Agostara B. Boccardo F, et al. Cancer Invest. 1997;15(6):505-12. doi: 10.3109/07357909709047591. Cancer Invest. 1997. PMID: 9412655 Clinical Trial.
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. [email protected].
Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, Giai M, Genta F, Pacini P, Distante V, Bolognesi A, Aldrighetti D, Farris A. Boccardo F, et al. J Clin Oncol. 2000 Jul;18(14):2718-27. doi: 10.1200/JCO.2000.18.14.2718. J Clin Oncol. 2000. PMID: 10894871 Clinical Trial.
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Boccardo F, Rubagotti A, Amoroso D, Sismondi P, Genta F, Nenci I, Piffanelli A, Farris A, Castagnetta L, Traina A, et al. Boccardo F, et al. Eur J Cancer. 1992;28(2-3):673-80. doi: 10.1016/s0959-8049(05)80123-6. Eur J Cancer. 1992. PMID: 1591091 Clinical Trial.
397 results